I-MAB Says Will Continue To Review Follow-Up Data From The Phase 2 Study Of Lemzoparlimab In HR-MDS; AbbVie Terminating Agreement Relating To Certain CD47 Antibody Compounds And Products
Portfolio Pulse from Benzinga Newsdesk
I-MAB announced it will continue to review follow-up data from the Phase 2 study of Lemzoparlimab in HR-MDS. Meanwhile, AbbVie is terminating its agreement related to certain CD47 antibody compounds and products.
September 22, 2023 | 8:13 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
AbbVie's termination of its agreement related to certain CD47 antibody compounds and products could potentially have a negative impact on its stock.
AbbVie's decision to terminate its agreement related to certain CD47 antibody compounds and products could be seen as a negative development by investors, potentially leading to a negative impact on the company's stock. However, the overall impact will depend on the importance of this agreement to AbbVie's business.
CONFIDENCE 70
IMPORTANCE 60
RELEVANCE 70
NEUTRAL IMPACT
I-MAB's decision to continue reviewing data from the Phase 2 study of Lemzoparlimab could potentially impact its stock positively if the results are favorable.
I-MAB's decision to continue reviewing data from the Phase 2 study of Lemzoparlimab indicates that the company sees potential in the drug. If the results are favorable, it could lead to a positive impact on the company's stock. However, the impact is uncertain until the results are disclosed.
CONFIDENCE 70
IMPORTANCE 60
RELEVANCE 70